About Rosetta Capital
Rosetta Capital is a venture capital firm founded in 2000. It is primarily based out of Aylesbury, United Kingdom. As of Oct 2025, Rosetta Capital has invested in 39 companies. It primarily invests in Series A round in Sweden based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and HealthTech. Most recently it participated in the $***** Series D round of Mission Therapeutics Overall, Rosetta Capital portfolio has seen 9 IPOs and 15 acquisitions including key companies like PTC Therapeutics, Immunocore and Aprea. A lot of funds co-invest with Rosetta Capital, with names like Karolinska Development sharing a substantial percentage of its portfolio. Rosetta Capital has team of 5 people including 4 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series C & 3 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
Rosetta Capital's List of Top Investments
Rosetta Capital has a portfolio of 39 companies. Their most notable investments are in Mission Therapeutics and Mission Therapeutics.Their portfolio spans across United States, Sweden, United Kingdom and 7 more locations. They have invested in Life Sciences, High Tech, HealthTech and 4 other sectors, across stages such as Series A, Series C and 3 more. Here is the list of top investments by Rosetta Capital:Developer of small molecule drugs for the treatment of rare diseases. The company's lead product Ataluren is an orally administered small-molecule drug for the treatment of cystic fibrosis and Duchenne muscular dystrophy caused by nonsense mutations. Also, developing anticancer and antibacterial drugs.
Key facts about PTC Therapeutics
- Founded Year: 1998
- Location: South Plainfield (United States)
- Annual Revenue: $1B+ as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $248M
- Employee Count: 1,145 as on Aug 31, 2026
- Investors: Brookside Capital, BB Biotech and 28 Others
- Latest Funding Round: Post IPO, May 16, 2023, $*****
- Highlight: Public
2. Immunocore
Developer of bispecific T cell receptor therapies for human diseases. These therapeutic agents utilize modular technology to modulate immune system activity. The mechanism involves targeting diseased cells to facilitate immune recognition and destruction or reducing immune responses in autoimmune conditions. The research and development focus includes applications for solid tumors, infectious diseases, and autoimmune disorders.
Key facts about Immunocore
- Founded Year: 2008
- Location: Abingdon (United Kingdom)
- Stage: Public
- Total Funding till date: $601M
- Employee Count: 611 as on Aug 31, 2026
- Investors: HTIF, RTW Investments and 50 Others
- Latest Funding Round: Post IPO, Jul 18, 2022, $*****
- Highlight: Public
Developer of small molecule inhibitors targeting specific disease associated enzymes. These therapeutic candidates focus on the regulation of cellular quality control processes to address neurodegenerative conditions, heart disease, kidney disease, and fibrosis. The research centers on the modulation of protein degradation pathways to influence disease progression.
Key facts about Mission Therapeutics
- Founded Year: 2011
- Location: Cambridge (United Kingdom)
- Annual Revenue: $1M - $10M as on Dec 31, 2016
- Valuation: $*****
- Stage: Series D
- Total Funding till date: $192M
- Employee Count: 11 - 50 as on Mar 01, 2026
- Investors: Rosetta Capital, Roche Enterprises and 46 Others
- Latest Funding Round: Series D, Oct 15, 2025, $*****
- Highlight: Editors' Pick
4. Aprea
Developer of small molecule therapeutics targeting tumor suppressor proteins. The company focuses on p53, a tumor suppressor protein that induces cell cycle arrest or cell death. The company's lead candidate is APR-246, that acts by reactivating mutant and defective native p53, leading to tumor cell death. The company is also developing APR-017, which induces p53-mediated apoptosis by restoring p53 activity in cancer cell lines with mutant p53.
Key facts about Aprea
- Founded Year: 2003
- Location: Boston (United States)
- Stage: Public
- Total Funding till date: $113M
- Investors: ADS Ventures, Janus Henderson Investors and 15 Others
- Latest Funding Round: Post IPO, Dec 09, 2025, $*****
- Highlight: Public
Provider of pericardial transcatheter aortic valve replacement and delivery system. It offers Trilogy Valve with locator technology that includes a root valve sewn onto a stent and a delivery system for the treatment of aortic valve stenosis for treatment of patients suffering from the aortic valve insufficiency.
Key facts about JenaValve Technology
- Founded Year: 2006
- Location: Irvine (United States)
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $364M
- Employee Count: 258 as on Aug 31, 2026
- Investors: Bain Capital Life Sciences, Kreos Capital and 19 Others
- Latest Funding Round: Series C, Dec 21, 2021, $*****
- Highlight: Acquired
Rosetta Capital's Year-on-Year Investment Trends
Rosetta Capital has invested in 39 companies over the last 13 years, with an average of 0 new investment annually in the last 10 years. In 2025, it made 1 investment. Its most recent first time investment was in Mission Therapeutics and most recent follow-on round was in Mission Therapeutics.Rosetta Capital's Investments by Stage
Rosetta Capital has made 2 investments in Series A stage with an average round size of $9.59M, 2 investments in Series C stage with an average round size of $19.5M, 1 investment in PE stage, 1 investment in Series B stage with an average round size of $66M and 1 investment in Series D stage with an average round size of $32.2M.Stage of entry | No. of Investments |
|---|---|
Series A | 2 |
Series C | 2 |
PE | 1 |
Series B | 1 |
Series D | 1 |
Note: We have considered here, only first round of investments
Rosetta Capital's Investments by Sector
Rosetta Capital has a diverse portfolio, with companies operating in the Life Sciences, Sustainability Tech, HealthTech, High Tech and Internet of Things - Industry Applications. Notably, it has invested in 36 Tech companies, 30 Enterprise (B2B) companies, 5 Software companies and at least 3 companies focusing on Consumer (B2C).Sector | No. of Investments |
|---|---|
Life Sciences | 7 |
Sustainability Tech | 4 |
HealthTech | 1 |
High Tech | 1 |
Internet of Things - Industry Applications | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Rosetta Capital's Investments by Geography
Rosetta Capital has made most investments in Sweden (3), followed by United Kingdom where it has made 2 investments.Country | No. of Investments |
|---|---|
Sweden | 3 |
United Kingdom | 2 |
Germany | 1 |
Switzerland | 1 |
Note: We have considered here, only first round of investments
Rosetta Capital's recent investments
Rosetta Capital has not made any investment in 2026 so far.Here are the most recent investments by Rosetta Capital:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Oct 15, 2025 | United Kingdom | Series D | 7452 | ||
Mar 14, 2024 | United Kingdom | Series D | 5546 | ||
Dec 01, 2022 | United Kingdom | Series C | 6930 | [+5] | |
Jun 04, 2022 | United Kingdom | Series C | 8227 | ||
Sep 27, 2016 | Sweden | Series A | 9593 |
IPOs and Publicly Listed companies in Rosetta Capital's Portfolio
9 of Rosetta Capital's portfolio companies have become public. Immunocore got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Feb 2021 at marketcap of $1.1B and Aprea got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $298M.Here are Rosetta Capital's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Feb 05, 2021 | - | - | 1328 | |
Oct 03, 2019 | - | - | 7332 | |
May 04, 2018 | - | - | 1442 | |
Sep 04, 2017 | - | - | 4721 | |
Oct 15, 2014 | - | - | 6775 |
Acquired companies in Rosetta Capital's Portfolio
15 companies from Rosetta Capital's portfolio have been acquired. The most recent acquisition was Oxular in Jan 2025 by Regeneron Pharmaceuticals for $*****.Here are Rosetta Capital's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jan 02, 2025 | - | - | 9038 | |
Oct 29, 2024 | - | - | 1729 | |
Jul 25, 2024 | - | - | 9519 | |
Jun 06, 2023 | - | - | 2651 | |
Jul 27, 2021 | - | - | 3955 |
Team profile of Rosetta Capital
Rosetta Capital has a team of 5 members including 4 Partners located in United Kingdom and Germany. Rosetta Capital's team does not sit on the board of any company as of now.Here is a list of all team members in Rosetta Capital:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | London | - | ||
Partner | - | - | ||
Partner | Munich | - | ||
Partner | London | - | - |
Co-investors of Rosetta Capital
Over the past 13 years, 42 investors have co-invested in Rosetta Capital's portfolio companies. This includes funds and angels.
- Invested before Rosetta Capital: Woodford Investment Management, Novartis Venture Fund and 24 others have invested in rounds before Rosetta Capital. There are 2 companies where Woodford Investment Management has invested before Rosetta Capital and 2 companies where Novartis Venture Fund has invested before Rosetta Capital.
- Top Co-investors of Rosetta Capital: 4 investors entered a company along with Rosetta Capital. These include investors like Karolinska Development (1 company).
- Invested after Rosetta Capital: A total of 12 investors have invested in Rosetta Capital's portfolio after their investments. Top Investors include The Michael J. Fox Foundation (1 company), Parkinsons (1 company) and Opocrin (1 company).
Recent News related to Rosetta Capital
•
Mission Therapeutics Secures $13.3M to Advance Parkinson's Candidate MTX325 Through Clinical TrialsPR Newswire•Oct 15, 2025•Mission Therapeutics, IP Group, Sofinnova Partners, Roche and 3 others
•
Sequana Medical announces update on second tranche of convertible bridge loanGlobeNewswire•Dec 02, 2024•Sequana Medical, EQT, Rosetta Capital
•
Swedish buyout group EQT plans to sell its stake in software group IFS for €15bnesdelatino.com•Sep 24, 2024•IFS, EQT, Sequana Medical, Rosetta Capital
•
Sequana Medical announces new amount of capital and new number of sharesGlobeNewswire•Jul 05, 2024•Sequana Medical, Rosetta Capital
•
Sequana Medical Successfully Raises Eur 11.5 Million In An Equity PlacementGlobeNewswire•Mar 21, 2024•Sequana Medical, KBC Securities, Rosetta Capital, Partners in Equity
•
Mission Therapeutics raises £25.2m to enhance power of mitochondriaBioPharma-Reporter•Mar 19, 2024•Pfizer, Sofinnova Partners, Roche, SR One and 3 others
•
Sequana medical announces eur 3.0 million convertible financing from major shareholders and agreement with lenders on deferral of debt service paymentsGlobeNewswire•Feb 08, 2024•Sequana Medical, Partners in Equity, Rosetta Capital
•
Carrick Therapeutics Announces $35 Million Investment from PfizerGlobeNewswire•Dec 01, 2022•Carrick Therapeutics, Pfizer, Arch Venture Partners, Rosetta Capital and 4 others
•
Rosetta Capital buys into Cambridge drug discovery firm’s ‘Mission’Business Weekly newspaper•Apr 07, 2021•Rosetta Capital, Mission Therapeutics
•
Revelation Partners Supports Rosetta’s Acquisition Of Seven Biotech AssetsPE Hub•Mar 30, 2021•Revelation Partners, Rosetta Capital, Schroders, Macfarlanes and 1 other
